Recon: Baxter resumes IV solution production at hurricane-impacted facility; Teva hit with €463M antitrust fine over Copaxone practices

• US FDA says lowest dose of Novo Nordisk's weight-loss drug now available (Reuters)
• Novo Nordisk’s Ozempic and Wegovy, long in shortage, are now listed as available by FDA (STAT)
• Purdue Pharma nears new bankruptcy deal with Sacklers, mediator says (Reuters)
• IQVIA lowers annual revenue forecast amid trial delays (Reuters)
• Baxter restarts IV solutions manufacturing line at hurricane-hit facility (Reuters)

• Mpox cases on African continent show 500% increase year-on-year (Reuters)
• Merck sees Gardasil China woes carrying into 2025 (Reuters)
• AstraZeneca’s China president is under investigation by authorities (STAT)
• Baxter exits China IV fluids market amid tough local competition, US shortage (Fierce)
• Bristol Myers earnings beat expectations, driven by sales of older drugs (Reuters)
• Japan's Takeda raises full-year profit forecast amid restructuring (Reuters)
• Teva fined $503 million for disparaging a rival and using patents to thwart competition (STAT)

• Regeneron shares drop as higher-dose Eylea drug misses sales estimates (Reuters)
• Haleon misses Q3 forecasts on stronger pound (Reuters)
• EMA Considers Cracking Down On Late Filings From Companies By Auto-Releasing Rapporteurs (Pink Sheet)
• AbbVie adds to T cell engager momentum, with EvolveImmune pact starting at $65M (Endpoints)
• Amgen makes pipeline cuts, but obesity plans remain the focus (Endpoints)
• National Academies calls to change how biomedical research uses race and ethnicity (STAT)
• Capricor and the FDA: A daring, risky filing strategy (STAT)
• Argenx reports Vyvgart sales streak, bolstered by launch in rare neuro disorder (Endpoints)
• Lexeo shares early data on Alzheimer’s gene therapy (Endpoints)
• Compass Pathways delays key Phase 3 psilocybin readouts, spurring 30% layoffs (Endpoints)
• Corcept misses primary endpoint in supportive Cushing's syndrome study (Endpoints)
• UCB's anti-tau Alzheimer's program fails Phase 2 primary endpoint, but highlights positive secondaries (Endpoints)
• Alvotech Petitions US FDA To Deny Interchangeability For Rival Stelara Biosimilars (Pink Sheet)
• AbbVie Slaps Mankind Away Until 2027 On US Lumigan Generic (Pink Sheet)
• Makena Active Ingredient Compounding Ban Gets US FDA Panel Nod (Pink Sheet)

• Teleflex shares slump as hurricane impact weighs on annual revenue forecast (Reuters)
• Siemens could reduce stakes in Healthineers, other companies to fund Altair deal (Reuters)
• Apple claims new AirPod hearing aid feature is ‘clinical grade.’ Is it? (STAT)
• TCT 2024: Valve under-expansion plagues Boston Scientific's head-to-head TAVR trial (Fierce)
• TCT 2024: J&J’s Abiomed clears pivotal study for shrinkable heart pump (Fierce)
• Roche collects more data to support blood tests for diagnosing Alzheimer’s disease (Fierce)
• Edwards, Medtronic and Inari share trial data at TCT conference (MedtechDive)
• Boston Scientific’s Acurate Neo2 inferior to rival TAVR valves in study (MedtechDive)

• Jazz Pharma Loses Lawsuit Over FDA Approval of Rival Sleep Drug (Bloomberg Law) (Endpoints)
• Two generic drugmakers pay $49 million to settle price-fixing charges (STAT)